EMEA-002312-PIP01-17-M02 - paediatric investigation plan

abrocitinib
PIPHuman

Key facts

Invented name
Cibinqo
Active Substance
abrocitinib
Therapeutic area
Dermatology
Decision number
P/0454/2023
PIP number
EMEA-002312-PIP01-17-M02
Pharmaceutical form(s)
  • Tablet
  • Age-appropriate oral liquid dosage form
Condition(s) / indication(s)
Treatment of atopic dermatitis
Route(s) of administration
Oral use
Contact for public enquiries

Pfizer Europe MA EEIG

Tel. +44 (0)1304 646 607
E-mail: pip_enquiries@pfizer.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

Share this page